8-K
filed April 27, 2023, 7:59 PM ET
ticker DXCM
CIK 0001093557
earnings
confidence high
sentiment positive
materiality 0.85
Dexcom Q1 revenue $741.5M (+18% YoY); raises FY 2023 guidance to $3.4-3.515B
DEXCOM INC
2023-Q1 EPS reported
$0.12
revenue$741,500,000
- Revenue $741.5M (+18% YoY, +19% organic); US +17%, Intl +21% reported (+27% organic).
- GAAP net income $48.6M ($0.12 diluted EPS); Non-GAAP net income $68.5M ($0.17 diluted EPS).
- GAAP operating income $47.2M (6.4% revenue); Non-GAAP operating income $78.6M (10.6% revenue).
- Initiated Dexcom G7 launch in US; CMS finalized coverage for G7 for Medicare beneficiaries.
- FY 2023 revenue guidance raised to $3.4-3.515B (17-21% growth); margin guidance reiterated.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
DEXCOM INC reported quarter ended March 31, 2023 results: revenue $741.5 million, net income $48.6 million, EPS $0.12 per diluted share. Guidance raised.
- Period
- quarter ended March 31, 2023
- Revenue
- $741.5 million
- Net income
- $48.6 million
- EPS
- $0.12 per diluted share
- Guidance
- raised
- Result
- reported results
Exact text from the filing
its financial results as of and for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights: • Revenue grew 18% versus the same quarter of the prior year to $741.5 million on a reported basis and 19% on an organic 1 basis. • U.S. revenue growth of 17% and international revenue growth of 21% on a reported basis. International revenue growth was 27%
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
DEXCOM INC reported fiscal year 2023 results: revenue approximately $3.400 - 3.515 billion. Guidance raised.
- Period
- fiscal year 2023
- Revenue
- approximately $3.400 - 3.515 billion
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
The company is updating fiscal year 2023 revenue guidance, and reiterating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin at the following levels: • Revenue of approximately $3.400 - 3.515 billion (17-21% growth)
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
DEXCOM INC reported first quarter of 2023 results: net income $48.6 million, EPS $0.12 per diluted share. Guidance raised.
- Period
- first quarter of 2023
- Net income
- $48.6 million
- EPS
- $0.12 per diluted share
- Guidance
- raised
- Result
- reported results
Exact text from the filing
First Quarter 2023 Financial Results Revenue: In the first quarter of 2023, worldwide revenue grew 18% to $741.5 million on a reported basis, up from $628.8 million in the first quarter of 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
DEXCOM INC reported first quarter of 2023 results: net income $48.6 million, EPS $0.12 per diluted share. Guidance raised.
- Period
- first quarter of 2023
- Net income
- $48.6 million
- EPS
- $0.12 per diluted share
- Guidance
- raised
- Result
- reported results
Exact text from the filing
Given the strength of our first quarter results and an expanding market opportunity with new CGM coverage now available, we are pleased to raise our 2023 revenue guidance.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
DEXCOM INC reported first quarter of 2023 results: net income $48.6 million, EPS $0.12 per diluted share. Guidance raised.
- Period
- first quarter of 2023
- Net income
- $48.6 million
- EPS
- $0.12 per diluted share
- Guidance
- raised
- Result
- reported results
Exact text from the filing
GAAP net income was $48.6 million, or $0.12 per diluted share, for the first quarter of 2023, compared to GAAP net income of $97.3 million, or $0.23 per diluted share, for the same quarter of 2022.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.